Gilead Sciences (GILD) : Morris Capital Advisors scooped up 1,334 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 63,495 shares of Gilead Sciences which is valued at $5,058,012.Gilead Sciences makes up approximately 3.36% of Morris Capital Advisors’s portfolio.
Other Hedge Funds, Including , Chilton Capital Management reduced its stake in GILD by selling 3,682 shares or 2.05% in the most recent quarter. The Hedge Fund company now holds 175,738 shares of GILD which is valued at $13,999,289. Gilead Sciences makes up approx 1.32% of Chilton Capital Management’s portfolio.Riverhead Capital Management reduced its stake in GILD by selling 391,876 shares or 51.83% in the most recent quarter. The Hedge Fund company now holds 364,173 shares of GILD which is valued at $29,010,021. Gilead Sciences makes up approx 0.48% of Riverhead Capital Management’s portfolio.Hm Payson Co boosted its stake in GILD in the latest quarter, The investment management firm added 2,777 additional shares and now holds a total of 236,984 shares of Gilead Sciences which is valued at $18,856,817. Gilead Sciences makes up approx 0.91% of Hm Payson Co’s portfolio.First Trust Advisors Lp reduced its stake in GILD by selling 123,881 shares or 18.54% in the most recent quarter. The Hedge Fund company now holds 544,298 shares of GILD which is valued at $43,767,002. Gilead Sciences makes up approx 0.13% of First Trust Advisors Lp’s portfolio. Contrarius Investment Management Ltd sold out all of its stake in GILD during the most recent quarter. The investment firm sold 62,288 shares of GILD which is valued $4,988,646.
Gilead Sciences closed down -0.96 points or -1.22% at $77.42 with 1,24,03,880 shares getting traded on Thursday. Post opening the session at $78.43, the shares hit an intraday low of $76.94 and an intraday high of $78.455 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Investors should note that on Jul 25, 2016, Gilead Sciences announced a cash dividend of $0.4700. The company’s management has announced Sep 14, 2016 as the ex-dividend date and fixed the record date on Sep 16, 2016. The payable date has been fixed on Sep 29, 2016.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Upgraded by Jefferies to ” Buy” on Sep 6, 2016. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.